IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Purchases 33,013 Shares of Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin acquired 33,013 shares of the business’s stock in a transaction on Tuesday, January 27th. The stock was acquired at an average cost of $1.48 per share, with a total value of $48,859.24. Following the acquisition, the insider directly owned 1,034,312 shares in the company, valued at approximately $1,530,781.76. This trade represents a 3.30% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Stock Up 29.4%

Shares of NASDAQ:IRIX opened at $0.88 on Thursday. The company’s 50 day moving average price is $0.73 and its two-hundred day moving average price is $0.95. IRIDEX Corporation has a 12-month low of $0.61 and a 12-month high of $1.65. The firm has a market cap of $15.46 million, a PE ratio of -4.40 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX) last announced its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The firm had revenue of $12.57 million for the quarter, compared to the consensus estimate of $13.59 million. On average, research analysts expect that IRIDEX Corporation will post -0.12 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, IRIDEX currently has an average rating of “Hold” and an average price target of $3.00.

Trending Headlines about IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

Institutional Investors Weigh In On IRIDEX

Large investors have recently bought and sold shares of the company. United Capital Financial Advisors LLC bought a new position in IRIDEX in the 2nd quarter valued at about $41,000. Weber Capital Management LLC ADV bought a new stake in shares of IRIDEX during the 2nd quarter worth approximately $206,616. Diversify Advisory Services LLC bought a new stake in shares of IRIDEX during the 2nd quarter worth approximately $30,000. Bank of New York Mellon Corp acquired a new stake in shares of IRIDEX during the 2nd quarter worth approximately $29,000. Finally, Renaissance Technologies LLC boosted its position in shares of IRIDEX by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock worth $401,000 after acquiring an additional 25,067 shares in the last quarter. 20.10% of the stock is currently owned by institutional investors and hedge funds.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.